Clinical review: Update on treatment of inflammatory macular edema.
Ossewaarde-van Norel
Annette
A
Department of Ophthalmology, University Medical Center Utrecht, Utrecht, The Netherlands. a.ossewaarde-vannorel@umcutrecht.nl
Rothova
Aniki
A
D000086:Acetazolamide / Q000627:therapeutic use; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000465:Algorithms; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D004343:Drug Implants / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000601:surgery; D013004:Somatostatin / Q000031:analogs & derivatives; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014605:Uveitis / Q000188:drug therapy / Q000601:surgery; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects; D014821:Vitrectomy
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D004343:Drug Implants; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D013004:Somatostatin; D007372:Interferons; D000086:Acetazolamide